All In MedTech

Device Trial Radar · NCT06458907

A Prospective, Randomized Multicenter Clinical Trial of the TricValve® Transcatheter Bicaval Valve System in Subjects With Severe Tricuspid Regurgitation.

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 780 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

780

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Nov 2028

Study completion Nov 2032

Sponsor

Lead sponsor
P+F Products + Features USA Inc.Not on our public-company list
Sponsor type
Industry
Collaborators
Meditrial USA Inc.
First posted
Jun 14, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Pivotal trial to evaluate the safety and effectiveness of the P\&F TricValve® Transcatheter Bicaval Valve System.

Conditions

  • Tricuspid Valve Disease
  • Heart Valve Diseases
  • Cardiovascular Diseases
  • Heart Failure
  • Tricuspid Valve Regurgitation
  • Tricuspid Valve Insufficiency

Interventions

  • TricValve SystemDevice

    • Heterotopic Transcatheter Valve Replacement (TVR) with the TricValve System in conjunction with optimal medical therapy

  • Optimal medical therapyDrug

    Optimal medical therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Randomized Cohort: Caval Reflux (CR) grade reductionTime frame: 6 months
  2. Randomized Cohort: Hierarchical composite endpoint including: Kansas City Cardiomyopathy Questionnaire (KCCQ) improvement, New York Heart Association (NYHA) functional class improvement, and 6-minute walk test distance improvementTime frame: 6 months
  3. Randomized Cohort: Rate of Major Adverse Events (MAE)Time frame: 30 days

2 more outcomes with a free account

Locations

34 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama

    Birmingham, Alabama

  • St. Joseph's Hospital and Medical Center

    Phoenix, Arizona

  • UC Davis Health

    Sacramento, California

31 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.